期刊： DIABETES THERAPY, 2022; 13 (1)
Introduction We evaluated the effect of dulaglutide on the relative contributions of fasting glucose (FG) and postprandial glucose (PPG) to overall hy......
期刊： DIABETES THERAPY, 2022; 13 (6)
Background TRUST-CHN is a prospective, post-marketing safety study in patients with type 2 diabetes mellitus (T2DM) in China to evaluate the safety an......
期刊： DIABETES THERAPY, 2022; 13 (11-12)
Introduction: While patients with diabetes are at higher risk of developing acute kidney injury (AKI), there are few studies on the recurrence of AKI ......
期刊： DIABETES THERAPY, 2022; 13 (10)
Introduction The objective of the current study was to assess the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1.0 mg versus dul......
期刊： DIABETES THERAPY, 2022; 13 (2)
Introduction Increased postprandial glucose (PPG) is associated with high glycated haemoglobin levels and is an independent risk factor for cardiovasc......
期刊： DIABETES THERAPY, 2022; 13 (7)
Introduction Sarcopenia is defined as a progressive and generalized muscle disorder that involves accelerated loss of muscle mass and impaired functio......
期刊： DIABETES THERAPY, 2022; 13 (7)
Introduction: Patients with diabetes mellitus and end-stage renal disease are at a high risk of developing coronary, cerebrovascular, and peripheral v......
期刊： DIABETES THERAPY, 2022; 13 (5)
Introduction Cardiovascular disease (CVD) is the leading cause of death in Chinese adults with type 2 diabetes (T2D), and treatment guidelines have in......
期刊： DIABETES THERAPY, 2022; 13 (6)
Introduction: LY2963016 insulin glargine (LY IGlar), a biosimilar of Lantus (R) insulin glargine (IGlar), demonstrated comparable efficacy and safety ......
期刊： DIABETES THERAPY, 2022; 13 (4)
Aim This study aimed to investigate the alteration of circulating CD34(+)KDR(+)CD133(+) endothelial progenitor cells (EPCs) in patients with newly dia......
期刊： DIABETES THERAPY, 2022; 13 (11-12)
Introduction Emerging evidence showed that adipocytes are important regulators in controlling insulin resistance in type 2 diabetes mellitus (T2DM). S......
期刊： DIABETES THERAPY, 2022; 13 (10)
Introduction We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to eva......
期刊： DIABETES THERAPY, 2021; 12 (9)
Introduction BEYOND 7 demonstrated that a higher starting dose (0.3 U/kg) of insulin glargine 100 U/mL (Gla-100) is as safe as the standard starting d......
期刊： DIABETES THERAPY, 2021; 12 (9)
Introduction To evaluate insulin injection knowledge, attitudes, and practices of nurses across China in order to provide reference for the formulatio......
